METHODS: PubMed and Scopus databases were exhaustively searched for publications on the use of the real-time ICG-FI evaluation of BC tumors with non-conventional breast imaging technologies.
RESULTS: Twenty-three studies were included in this review. ICG-FI has been used for BC tumor identification in 12 orthotopic animal tumor experiences, 4 studies on animal assessment, and for 7 human clinical applications. The BC tumor-to-background ratio (TBR) was 1.1-8.5 in orthotopic tumor models and 1.4-3.9 in animal experiences. The detection of primary human BC tumors varied from 40% to 100%. The mean TBR reported for human BC varied from 2.1 to 3.7. In two studies evaluating BC surgical margins, good sensitivity (93.3% and 100%) and specificity (60% and 96%) have been reported, with a negative predictive value of ICG-FI to predict margin involvement intraoperatively of 100% in one study.
CONCLUSIONS: The use of ICG-FI as a guiding tool for the real-time identification of BC tumors and for the assessment of tumor boundaries is promising. There is great variability between the studies with regard to timing and dose. Further evidence is needed to assess whether ICG-guided BC surgery may be implemented as a standard of care.
方法:对PubMed和Scopus数据库进行详尽搜索,寻找使用非常规乳腺成像技术对BC肿瘤进行实时ICG-FI评估的出版物。
结果:本综述包括23项研究。ICG-FI已用于12种原位动物肿瘤的BC肿瘤鉴定,关于动物评估的4项研究,以及7种人体临床应用。在原位肿瘤模型中,BC肿瘤背景比(TBR)为1.1-8.5,在动物实验中为1.4-3.9。原发性人类BC肿瘤的检测从40%到100%不等。报告的人BC的平均TBR在2.1至3.7之间变化。在两项评估BC手术切缘的研究中,已经报道了良好的灵敏度(93.3%和100%)和特异性(60%和96%),在一项研究中,ICG-FI的阴性预测值可预测术中边缘受累为100%。
结论:使用ICG-FI作为指导工具实时识别BC肿瘤和评估肿瘤边界是有希望的。关于时间和剂量的研究之间存在很大的差异。需要进一步的证据来评估ICG引导的BC手术是否可以作为护理标准来实施。